Odyssey Health, Inc. (ODYY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Odyssey Health, Inc. (ODYY) trades at $0.0099. Odyssey Health, Inc. is a medical company focused on developing and acquiring medical products and health-related technologies. Their portfolio includes devices for heart monitoring, choking rescue, and concussion treatment. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for ODYY: ODYY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ODYY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on ODYY.
How is this calculated? →Odyssey Health, Inc. (ODYY) Healthcare & Pipeline Overview
Odyssey Health, Inc. develops and acquires medical devices, including CardioMap for heart monitoring, Save A Life for choking rescue, and ONP-002 for mild brain trauma. The company operates within the competitive medical device sector, focusing on innovative solutions for unmet healthcare needs.
What Is the Investment Thesis for ODYY?
Odyssey Health, Inc. presents a speculative investment opportunity within the medical device sector. The company's focus on developing and acquiring medical products and health-related technologies, including CardioMap, Save A Life, and ONP-002, could drive future growth if these products gain regulatory approval and market acceptance. However, the company's small market capitalization of $0.01 billion and negative beta of -1.08 indicate high volatility and sensitivity to market conditions. The absence of a dividend reflects a focus on reinvesting earnings into research and development. Successful commercialization of ONP-002 for concussion treatment represents a significant potential catalyst, but clinical trial outcomes and regulatory hurdles pose substantial risks. Investors should carefully consider the company's limited financial resources and competitive landscape before investing.
Based on FMP financials and quantitative analysis
ODYY Key Highlights
Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
- Development of CardioMap heart monitoring device aims to address a significant market need for early cardiac abnormality detection.
- ONP-002, a treatment for mild brain trauma or concussion, represents a potential breakthrough in neurological health.
- The company's focus on acquiring and developing medical technologies could lead to strategic partnerships or acquisitions.
- Incorporated in 2014, Odyssey Health is still in its early stages of development, offering potential for long-term growth.
Who Are ODYY's Competitors?
ODYY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ODYY's Key Strengths?
Innovative product pipeline with potential for significant market impact.
- Focus on addressing unmet needs in the healthcare sector.
- Proprietary technology and patents protecting key products.
- Experienced management team with expertise in medical device development.
What Are ODYY's Weaknesses?
Limited financial resources and small market capitalization.
- Dependence on successful clinical trials and regulatory approvals.
- Lack of established sales and marketing infrastructure.
- High concentration of risk in a few key products.
What Could Drive ODYY Stock Higher?
Clinical trial results for ONP-002 in concussion treatment (2027-2029).
- Expansion of CardioMap distribution network (2026-2028).
- Strategic partnerships and licensing agreements (Ongoing).
- Potential acquisitions of complementary medical device technologies (Ongoing).
What Are the Key Risks for ODYY?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approval for ONP-002.
- Competition from established medical device companies.
- Product liability risks and potential recalls.
- Limited financial resources and dependence on external funding.
- Changes in healthcare reimbursement policies.
What Are the Growth Opportunities for ODYY?
- Expansion of CardioMap: CardioMap, a heart monitoring and screening device, has the potential to capture a significant share of the cardiac diagnostics market, estimated at $25 billion globally. By expanding its distribution network and securing partnerships with hospitals and clinics, Odyssey Health can increase adoption of CardioMap and generate revenue growth. Timeline: 2026-2028.
- Commercialization of Save A Life: The Save A Life choking rescue devices address a critical need for preventing asphyxiation. With increasing awareness of choking hazards, particularly among children and the elderly, Odyssey Health can capitalize on this market by expanding its product line and distribution channels. The global market for emergency medical devices is projected to reach $30 billion by 2027. Timeline: 2026-2028.
- Development and Approval of ONP-002: ONP-002, a treatment for mild brain trauma or concussion, represents a significant growth opportunity for Odyssey Health. The market for concussion treatment is estimated at $8 billion, and successful clinical trials and regulatory approval could lead to substantial revenue generation. Timeline: 2027-2029.
- Strategic Acquisitions: Odyssey Health can pursue strategic acquisitions of complementary medical device companies or technologies to expand its product portfolio and market reach. This approach can accelerate growth and diversify revenue streams. The medical device industry is highly fragmented, providing numerous acquisition opportunities. Timeline: Ongoing.
- Partnerships and Licensing Agreements: Collaborating with larger medical device companies or pharmaceutical firms through partnerships and licensing agreements can provide Odyssey Health with access to additional resources, expertise, and distribution channels. This strategy can accelerate the commercialization of its products and reduce financial risk. Timeline: Ongoing.
What Are ODYY's Competitive Advantages?
- Proprietary technology in CardioMap heart monitoring device.
- Patents protecting Save A Life choking rescue devices.
- Potential market exclusivity for ONP-002 concussion treatment.
- First-mover advantage in specific niche markets.
What Does ODYY Do?
Odyssey Health, Inc., incorporated in 2014 and based in Las Vegas, Nevada, is a medical company dedicated to the development and acquisition of innovative medical products and health-related technologies. The company's mission is to address unmet needs in the healthcare sector through the creation and commercialization of cutting-edge medical devices. Odyssey Health's portfolio includes CardioMap, a heart monitoring and screening device designed to provide early detection of cardiac abnormalities. Additionally, they offer Save A Life, a suite of choking rescue devices aimed at preventing asphyxiation. A key product candidate in their pipeline is ONP-002, a treatment for mild brain trauma or concussion, representing a significant focus on neurological health. Formerly known as Odyssey Group International, Inc., the company has evolved to concentrate on medical solutions, seeking to improve patient outcomes and quality of life through technological advancements in healthcare.
What Products and Services Does ODYY Offer?
- Develops CardioMap, a heart monitoring and screening device.
- Creates Save A Life choking rescue devices.
- Focuses on ONP-002 for the treatment of mild brain trauma or concussion.
- Acquires medical products and health-related technologies.
- Aims to improve patient outcomes through innovative medical solutions.
- Seeks to address unmet needs in the healthcare sector.
How Does ODYY Make Money?
- Develops and patents medical device technologies.
- Seeks regulatory approvals for its products.
- Commercializes its products through direct sales, partnerships, and distribution agreements.
- Acquires existing medical device companies and technologies to expand its portfolio.
What Industry Does ODYY Operate In?
Odyssey Health, Inc. operates within the medical device industry, a sector characterized by rapid innovation and stringent regulatory requirements. The global medical device market is projected to reach $600 billion by 2026, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. Competition is intense, with established players like Medtronic and Johnson & Johnson, as well as numerous smaller companies vying for market share. Odyssey Health's success depends on its ability to develop and commercialize innovative products that address unmet clinical needs and navigate the complex regulatory landscape.
Who Are ODYY's Key Customers?
- Hospitals and clinics that use CardioMap for heart monitoring.
- Emergency medical service providers who utilize Save A Life choking rescue devices.
- Patients who suffer from mild brain trauma or concussion and may benefit from ONP-002.
- Consumers purchasing choking rescue devices for home use.
Financial Health
Odyssey Health, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Odyssey Health, Inc. stands at 41.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Odyssey Health, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Joseph Michael Redmond. ODYY has traded publicly since 2021.
Insider Activity
The most recent 12 insider filings for Odyssey Health, Inc. break down as 1 sales and 11 purchases. On net that is roughly 2.8M shares acquired (about $281K) — insiders putting money in tends to read as conviction.
ODYY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative product pipeline with potential for significant market impact.
- Focus on addressing unmet needs in the healthcare sector.
- Proprietary technology and patents protecting key products.
- Experienced management team with expertise in medical device development.
Bear Case
- Limited financial resources and small market capitalization.
- Dependence on successful clinical trials and regulatory approvals.
- Lack of established sales and marketing infrastructure.
- High concentration of risk in a few key products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
ODYY Latest News
No recent news available for ODYY.
ODYY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ODYY.
Price Targets
Wall Street price target analysis for ODYY.
ODYY MoonshotScore
What does this score mean?
The MoonshotScore rates ODYY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
ODYY OTC Market Information
ODYY trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Odyssey Health, Inc. Healthcare Stock: Key Questions Answered
What does Odyssey Health, Inc. do?
Odyssey Health, Inc. is a medical device company focused on developing, acquiring, and commercializing innovative medical products and health-related technologies. Their portfolio includes CardioMap, a heart monitoring and screening device; Save A Life choking rescue devices; and ONP-002, a treatment for mild brain trauma or concussion. The company aims to address unmet needs in the healthcare sector by providing solutions for cardiac diagnostics, emergency medical care, and neurological health.
What are the main risks for ODYY?
The main risks for Odyssey Health, Inc. include its limited financial resources, dependence on successful clinical trials and regulatory approvals, and intense competition from established medical device companies. Failure to obtain regulatory approval for ONP-002 or other products could significantly impact the company's prospects. Product liability risks and potential recalls also pose a threat. Changes in healthcare reimbursement policies could affect the adoption of its products.
How does Odyssey Health, Inc. navigate regulatory approval processes?
As a medical device company, Odyssey Health, Inc. must navigate stringent regulatory approval processes to commercialize its products. The company works with regulatory agencies like the FDA to ensure its products meet safety and efficacy standards. This involves conducting clinical trials, submitting regulatory filings, and complying with post-market surveillance requirements. The success of Odyssey Health, Inc. depends on its ability to navigate these complex regulatory pathways efficiently and effectively.
What is Odyssey Health, Inc.'s drug pipeline status?
Odyssey Health, Inc.'s primary drug candidate is ONP-002, which is being developed for the treatment of mild brain trauma or concussion. The company is currently focused on completing clinical trials to evaluate the safety and efficacy of ONP-002. The timeline for regulatory approval and commercialization depends on the outcome of these trials. The company's pipeline is relatively narrow, with ONP-002 representing a significant portion of its potential future revenue.
What are the key factors to evaluate for ODYY?
Evaluate ODYY on fundamentals, analyst consensus, and risk factors. Odyssey Health, Inc. presents a speculative investment opportunity within the medical device sector. Not financial advice.
How frequently does ODYY data refresh on this page?
ODYY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ODYY's recent stock price performance?
Odyssey Health, Inc. (ODYY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline with potential for significant market impact. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ODYY overvalued or undervalued right now?
Odyssey Health, Inc. (ODYY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The company's future performance is subject to various risks and uncertainties.